26 June 2020 

US-based biotech firm Avalon GloboCare has collaborated with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria, to develop an S-layer vaccine against Covid-19 for intranasal or oral administration. The partners are working to develop a vaccine candidate that would trigger an immune response sufficient to prevent a severe form of Covid-19 infection.

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended the conditional marketing authorisation of Gilead Sciences’ remdesivir under the brand name Veklury for Covid-19 patients aged 12 years and above with pneumonia who require supplemental oxygen. The drug is the first Covid-19 medicine to be recommended for authorisation in the European Union (EU).

The Federal University of Sao Paulo (Unifesp), Brazil is in discussions to assess a Covid-19 vaccine candidate developed by Italian researchers at Lazzaro Spallanzani National Institute, as reported by Reuters. The Italian researchers intend to perform mid-stage and final Phase III trials in Brazil.

Theravance Biopharma has dosed first patient in the Phase II clinical trial of TD-0903 to treat hospitalised patients with acute lung injury (ALI) caused by Covid-19 infection. TD-0903 is believed to be able to block the cytokine storm related to ALI and prevent progression to acute respiratory distress syndrome (ARDS).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.